Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krocker J, Nekljudova V, Loibl S, GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer 2023; 194:113324.
07.09.2023
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
07.09.2023
Eur J Cancer 2023; 194:113324
Schmidt Marcus, Nitz Ulrike A, Reimer Toralf, Schmatloch Sabine, Graf Heiko, Just Marianne, Stickeler Elmar, Untch Michael, Runnebaum Ingo B, Belau Antje, Huober Jens, Jackisch Christian, Hofmann Manfred, Krocker Jutta, Nekljudova Valentina, Loibl Sibylle, GBG/AGO-B, NOGGO/WSG study groups
Weiter
